Phase 2WithdrawnINTERVENTIONAL
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
ClinicalTrials.gov · NCT04276597 · Registry updated: 2023-03-10
- Condition / research focus
- Pulmonary Neuroendocrine Neoplasm; Pheochromocytoma; Paraganglioma; Thymus Carcinoid; Unknown Primary Tumors; Neuroendocrine Tumors; Neuroendocrine Skin Carcinoma; Neuroendocrine Breast Tumor; Neuroendocrine Carcinoma Metastatic; Neuroendocrine Neoplasm of Ovary
- Sponsor
- Excel Diagnostics and Nuclear Oncology Center
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2020-03-04. Completion: 2021-07-15 (may be estimated). No results posted in this registry response.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- 177Lu-DOTATOC (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Excel Diagnostics and Nuclear Oncology Center
Houston, Texas, United States
Site recruitment: Not reported